About the only good news for Amylin Pharmaceuticals Inc. Wednesday was that investors were unlikely to pay mind to the fact that third-quarter sales of diabetes drug Byetta (exenatide) missed analyst expectations, as shares of the San Diego-based biotech were hammered on a complete response letter and the prospect of a two-year delay for its once-weekly version of the GLP-1 agonist. (BioWorld Today)
Pfizer Inc. picked up rights to biosimilar versions of insulin in a potential $350 million-plus partnership with Indian biotech Biocon Ltd. that gives the big pharma firm access to the multibillion-dollar insulin space, as well as immediate inroads to emerging markets. (BioWorld Today)
Having yet to sign a partnership for hepatitis C drug ANA598, Anadys Pharmaceuticals Inc. is pulling in $25 million in a public offering to support an upcoming Phase IIb study of the non-nucleoside polymerase inhibitor. (BioWorld Today)
Genzyme Corp. reported promising five-year data from its Phase II extension study of alemtuzumab in relapsing-remitting multiple sclerosis (MS), news that could bode well for CD52-targeting drug as it looks to compete in the estimated $14 billion MS market. (BioWorld Today)
